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Background
The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated
in one-year prospective trials. Since normalization of cardiac T2* takes several years, the effi-
cacy and safety of deferasirox was assessed for two years in patients with β-thalassemia major
in the cardiac sub-study of the EPIC trial.
Design and Methods
Eligible patients with myocardial T2* greater than 5 to less than 20 ms received deferasirox,
with the primary endpoint being the change in T2* from baseline to two years.
Results
Baseline myocardial T2* was severe (>5 to <10 ms) in 39 patients, and moderate-to-mild (10 to
<20 ms) in 62 patients. Mean deferasirox dose was 33.1±3.7 mg/kg/d in the one-year core study
increasing to 36.1±7.7 mg/kg/d during the second year of treatment. Geometric mean myocar-
dial T2* increased from a baseline of 11.2 to 14.8 ms at two years (P<0.001). In patients with
moderate-to-mild baseline T2*, an increase was seen from 14.7 to 20.1 ms, with normalization
(≥20 ms) in 56.7% of patients. In those with severe cardiac iron overload at baseline, 42.9%
improved to the moderate-to-mild group. The incidence of drug-related adverse events did not
increase during the extension relative to the core study and included (≥5%) increased serum
creatinine, rash and increased alanine aminotransferase. 
Conclusions
Continuous treatment with deferasirox for two years with a target dose of 40 mg/kg/d contin-
ued to remove iron from the heart in patients with β-thalassemia major and mild, moderate and
severe cardiac siderosis. (Clinicaltrials.gov identifier: NCT 00171821)
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Introduction
Iron chelation therapy has markedly improved survival
for many patients with β-thalassemia major; however,
heart failure due to myocardial iron deposition has, until
recently, been the leading cause of death.1-3 Accurate meas-
urement of cardiac iron levels is important as common
assessment methods of total body iron alone, such as
measurement of serum ferritin and liver iron concentra-
tion (LIC), do not reliably predict myocardial iron status.4,5
This may be due to different rates of iron entry/clearance
from cardiomyocytes and hepatocytes,6 or other as yet
unidentified factors. T2* cardiovascular magnetic reso-
nance (CMR) provides rapid and direct assessment of car-
diac iron content and is useful in evaluating cardiac
responses to iron chelation therapy.7,8 Myocardial tissue
iron concentration has a non-linear relationship with T2*.9
Myocardial T2* values below 20 ms indicate myocardial
iron overload and values less than 10 ms are associated
with an increased likelihood of heart failure and arrhyth-
mia.8 As such, based on myocardial T2* assessments,
patients requiring intensive iron chelation can be identi-
fied and treated earlier in an attempt to avoid the mortali-
ty associated with heart failure.3
The efficacy of iron chelation therapy in reducing cardiac
iron levels based on myocardial T2* assessments has been
demonstrated in several prospective clinical trials; however,
all had a treatment duration of up to a maximum of one
year.10-13 As iron clears more slowly from the heart than the
liver,6 normalization of myocardial T2* may take several
years of iron chelation therapy. It is, therefore, essential that
the long-term efficacy and safety of any such therapy is
assessed prospectively. In the EPIC (Evaluation of Patients’
Iron Chelation with Exjade) cardiac sub-study, deferasirox
significantly improved geometric mean myocardial T2*
from a baseline of 11.2 to 12.9 ms (+16%, P<0.0001) with
significant concomitant improvements in both serum fer-
ritin and LIC over one year.13 Patients in the cardiac sub-
study of the EPIC trial have now received deferasirox ther-
apy for two years in an extension to the core trial.
Design and Methods
The cardiac substudy of EPIC was a prospective, open-label,
multicenter study conducted over a core period of one year. The
study was extended, allowing continuous treatment to all
patients who completed the one-year core study. LIC was
assessed by magnetic resonance (MR) measurements of the trans-
verse relaxation parameter R2, a method that demonstrates a
high degree of sensitivity and specificity compared with biopsy
LIC measurements.14 R2 scans were performed using FerriScan
(Resonance Health, Perth, Australia) according to standardized
procedures at individual sites. A full description of the study
design and inclusion/exclusion criteria has been previously pub-
lished;13 however, the key information relevant to this analysis is
summarized here.
Patient recruitment and dosing schedule
Patients with β-thalassemia aged 10 years or over with
myocardial T2* greater than 5 to less than 20 ms (indicating car-
diac siderosis) and left ventricular ejection fraction (LVEF) of 56%
or over as assessed by CMR were eligible for enrollment. In addi-
tion, serum ferritin levels of greater than 2,500 ng/mL, MR-
assessed (R2) LIC greater than 10 mg Fe/g dry weight (dw) and a
lifetime minimum of 50 transfused blood units were required. At
the end of the core one-year study, patients were invited to enter
an extension study for an additional year of treatment with
deferasirox; those who chose not to continue the study did not
have to provide a reason. Patients continued to receive
deferasirox in the extension based on the last dose received in the
core one-year study. Dose adjustments were based on serum fer-
ritin trends (assessed at 3-month intervals), myocardial T2*
assessments every six months and safety parameters (serum cre-
atinine, transaminases and adverse events [AEs]). Dose increases
up to 45 mg/kg/d were considered in patients with minimal
worsening of cardiac T2* (≤33% from baseline) or no improve-
ment in T2* (≤25% from baseline) provided that LIC was at least
3 mg Fe/g dw at the 6-monthly follow-up assessments. Dose
increases beyond 40 mg/kg/d had to be approved by the Study
Monitoring Committee and study sponsor. Patients were with-
drawn from the sub-study and treated with appropriate standard
of care if they had a decrease in cardiac T2* by more than 33%
from baseline or a decrease in LVEF to between 50% and less
than 56% with no improvement to 56% or more on a repeat
assessment within three months of the initial assessment. The
study was approved by the Independent Ethics Committee at
each participating center, and all patients (or parents/guardians)
provided written, informed consent before being allowed to
enter the extension study. The study was conducted in accor-
dance with Good Clinical Practice guidelines and the Declaration
of Helsinki.
Assessments
The primary efficacy endpoint of the extension trial was
change in myocardial T2* from baseline (of the core one-year
study) to two years. Myocardial T2* was assessed at baseline,
then every six months. Secondary efficacy endpoints included
change from baseline in LVEF and LIC after 24 months. Serum
ferritin levels were also measured at baseline and then monthly
until the end of the extension study. Safety was evaluated
monthly through monitoring and recording of AEs and routine
laboratory testing, including hematology, blood chemistry and
urine renal function assessments. A history of hepatitis was
recorded as part of the patient history without serological testing. 
Statistical methods
The primary efficacy endpoint was assessed in all patients who
entered the extension and who received the study medication.
Myocardial T2* measurements reported at the end of the exten-
sion included patients who had their last CMR scan performed at
month 18 or month 24 (using last-observation-carried-forward
[LOCF] analysis). The second year LOCF value was also used for
the analysis of LVEF, LIC and serum ferritin data. LVEF and LIC
are presented as mean ± standard deviation (SD), serum ferritin is
presented as median (range), and myocardial T2* as the geomet-
ric mean (anti-log of the mean of the log data) ± the coefficient of
variation (CV), equivalent to the variance of the mean in log
scale. The correlation between change from baseline in LIC versus
cardiac T2* was assessed using Pearson’s correlation coefficient
and regression analysis. Safety was assessed in all patients who
received at least one dose of study medication. Statistical signifi-
cance was established using a paired Student’s t-test at a two-
sided α level of 0.05; this was based on the log-transformed eval-
uations for myocardial T2* assessments.
Results
Patients’ characteristics
In total, 105 patients with cardiac siderosis completed
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the one-year core sub-study.13 Of these patients, 101 chose
to enter the one-year extension (for whom data are pre-
sented) and their baseline characteristics at enrollment are
shown in Table 1. Baseline myocardial T2* was greater
than 5 to less than 10 ms (severe cardiac siderosis) in 39
patients (38.6%) and 10 to less than 20 ms (moderate-to-
mild cardiac siderosis) in 62 patients (61.4%). 
Deferasirox dosing
In patients who continued in the extension study, the
mean (± SD) actual deferasirox dose received over the 2-
year treatment period was 34.5±4.8 mg/kg/d; this was
33.1±3.7 mg/kg/d during the one-year core study increas-
ing to 36.1±7.7 mg/kg/d during the one-year extension. In
patients with severe cardiac siderosis (baseline myocardial
T2* >5 to <10 ms), the mean dose over two years was
34.8±4.7 mg/kg/d (32.6±4.0 mg/kg/d during the core and
37.5±6.6 mg/kg/d during the extension) and in patients
with moderate-to-mild cardiac siderosis (baseline T2* 10
to <20 ms), the mean dose over two years was 34.3±4.8
mg/kg/d (33.5±3.5 mg/kg/d during the core and 35.3±8.2
mg/kg/d during the extension). During the 2-year study,
several dose increases to 40 mg/kg/d or over were pre-
scribed; 63 (62.4%) patients received dose increases from
30 to 40 mg/kg/d, 28 (27.7%) received an increase from 35
to 40 mg/kg/d, 13 (12.9%) received an increase from 40 to
45 mg/kg/d and one patient received an increase from 40
to 50 mg/kg/d. At the end of the one-year core phase, 71
patients (70.3%) were receiving deferasirox doses of 40
mg/kg/d and 2 (2.0%) were receiving 45 mg/kg/d. At the
end of two years, 54 patients (53.5%) were receiving 40
mg/kg/d, 10 (9.9%) were receiving 45 mg/kg/d and 2 were
receiving 47 and 51 mg/kg/d, respectively (Figure 1).
Over the two years, deferasirox dose was increased at
least once in 97 of 101 (96.0%) patients, as per the study
protocol. The overall median time to the first dose
increase was 21.7 weeks (range 0–87), thus occurring dur-
ing the core study. Once patients had entered the exten-
sion study, 42 (41.6%) patients had at least one dose
increase; the median time to the first dose increase in the
extension was 64 weeks (range 52–101). During the 2-year
study, there were 89 dose reductions in 43 patients
(42.6%); 59 (66.3%) of those were due to investigator-
assessed clinically significant laboratory test abnormalities
or AEs, 21 (23.6%) were according to protocol (e.g.
changes in patient weight, serum ferritin, etc.), 8 (9.0%)
were due to disease improvement and one (1.1%) due to
dosing error. In all patients, the most common AEs requir-
ing dose adjustments or interruptions included clinically
significant increases in serum creatinine (n=23; 22.8%),
increased alanine aminotransferase (n=6; 5.9%) and
increased aspartate aminotransferase (n=6; 5.9%); 5 of the
6 patients with increased alanine aminotransferase also
had increased aspartate aminotransferase. Mean transfu-
sional iron intake in all patients was 0.34± 0.15 mg/kg/d
over the 2-year treatment period (0.37±0.16 mg/kg/d for
patients with T2* >5 to <10 ms; 0.32±0.13 mg/kg/d for
patients with T2* 10 to <20 ms). 
Effect of deferasirox on myocardial iron 
and cardiac function
Myocardial T2* improved significantly from a core
baseline of 11.2 ms±40.8% to 14.8 ms±61.2% at two
years (Figure 2; P<0.001 LOCF). This represents an overall
mean relative increase from baseline of 17.7% in the first
year and 36.8% in the second year for all patients.
Significant increases in myocardial T2* were noted both in
the subgroup with severe myocardial iron overload (base-
line myocardial T2* >5 to <10 ms) from 7.3 ms±19.2% to
8.7 ms±34.8% and in the subgroup with moderate-to-
mild myocardial iron overload (baseline myocardial T2*
10 to <20 ms) from 14.7 ms±20.6% to 20.1 ms±44.1%
(P<0.001 LOCF for both). For patients with data in the
extension (myocardial T2* values at 18 or 24 months),
improvement in cardiac T2* (defined as >4% increase)
was reported in 72 patients (75.8%), no change in T2* was
D.J. Pennell et al.
haematologica | 2011; 96(1)
Table 1. Patients’ characteristics at baseline.
Myocardial T2* Myocardial T2* All 
>5 to <10 ms 10 to <20 ms patients
(n=39) (n=62) (n=101)
Mean age ± SD, years 21.4±5.9 20.1±8.0 20.6±7.3
Age group in years, n (%)
10–<16 7 (17.9) 22 (35.5) 29 (28.7)
≥16 32 (82.1) 40 (64.5) 72 (71.3)
Male:female, n 17:22 31:31 48:53
Race (Caucasian:Oriental:other), n 15:23:1 18:39:5 33:62:6
History of hepatitis B and/or C, n (%) 12 (30.8) 16 (25.8) 28 (27.7)
History of splenectomy, n (%) 20 (51.3) 30 (48.4) 50 (49.5)
Previous iron chelation therapy, n (%)
Deferoxamine monotherapy 23 (59.0) 45 (72.6) 68 (67.3)
Deferoxamine + deferiprone 16 (41.0) 17 (27.4) 33 (32.7)
Mean time since first 15.7±7.4 13.8±7.6 14.6±7.5
chelation ± SD, years
Mean number of transfusion 17.1±6.8 16.2±7.4 16.5±7.1
sessions in the year prior (10–34) (8–44) (8–44)
to study entry ± SD (range)†
Geometric mean baseline 7.3±19.4 14.7±20.6 11.2±40.8
myocardial T2* ± CV%, ms
Mean baseline LIC ± SD, mg Fe/g dw 28.4±10.2 28.1±10.2 28.2±10.2
Median baseline serum ferritin 7,185 4,893 5,350
(range), ng/mL (1,643–15,895) (1,689–16,944) (1,643–16,944)
†Information on the number of transfusions is only available for the year prior to study entry.
Figure 1. Planned deferasirox doses at core baseline, end of the one-
year core and end of the one-year extension study in all patients.
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reported in 9 patients (9.5%), and worsening of T2* (>4%
decrease) in 14 patients (14.7%). Improvement in myocar-
dial T2* was seen in 71.4% and 78.3% of patients with
severe and moderate-to-mild cardiac siderosis (baseline
T2* >5 to <10 ms and 10 to <20 ms), respectively. In
patients with severe baseline myocardial iron overload,
42.9% improved to myocardial T2* 10 to less than 20 ms
at two years, and 56.7% of patients with moderate-to-
mild baseline myocardial iron overload achieved a normal
myocardial T2* (≥20 ms). Cardiac T2* also continued to
improve in patients receiving at least one dose decrease
due to laboratory test abnormalities (11.2 ms±41.7% at
baseline; 14.7 ms±52.0% after two years).
LVEF remained stable and in the normal range over the
two years (Figure 3; baseline: 67.5±5.7%; two years:
67.7±5.1%; P=0.72 LOCF). Comparable results were
observed in both subgroups of patients with baseline T2*
greater than 5 to less than 10 ms (baseline: 66.1±5.3%;
two years: 66.5±5.5%, P=0.57 LOCF) and 10 to less than
20 ms (baseline: 68.4±5.8%; two years: 68.4±4.7%,
P=0.98 LOCF). Five patients developed LVEF less than
56% during the trial, 4 of whom had myocardial T2*
greater than 5 to less than 10 ms and one with myocardial
T2* 10 to less than 20 ms at baseline. This occurred at
month 12 and month 18 in 2 of these patients, respective-
ly, one of whom was noted to be non-compliant with
therapy. Both patients subsequently discontinued the trial
due to unsatisfactory therapeutic effect. The remaining 3
patients completed the trial; LVEF had improved to at least
56% in 2 patients by month 24 and was reduced by 5%
from baseline to 55% in one patient only at month 24.
Effect of deferasirox on LIC and serum ferritin levels
At two years, mean LIC was significantly reduced from
a baseline of 28.2±10.2 to 17.6±14.3 mg Fe/g dw in the
overall population, representing a reduction of 38.8%
(Figure 4; absolute change from baseline –10.7±12.7 mg
Fe/g dw; P<0.001 LOCF). Mean LIC was also significantly
reduced in patients with baseline myocardial T2* greater
than 5 to less than 10 ms from 28.4±10.2 to 20.9±15.6 mg
Fe/g dw representing a 28.0% reduction (absolute change
from baseline –7.7±12.8 mg Fe/g dw; P=0.0012 LOCF) and
in patients with baseline myocardial T2* 10 to less than 20
ms from 28.1±10.2 to 15.8±13.3 mg Fe/g dw representing
44.9% reduction (absolute change from base-
line –12.4±12.4 mg Fe/g dw; P<0.001 LOCF). There was a
significant negative correlation between the change in LIC
and change in cardiac T2* (r=–0.47, P<0.0001). For
patients with LIC data in the extension, 32 patients
(33.3%) achieved a LIC of less than 7 mg Fe/g dw.
Similarly, median serum ferritin was significantly
decreased from a baseline of 5,350 ng/mL (range
1,643–16,944 ng/mL) to 3,267 ng/mL (range 197–29,681
ng/mL) at two years in the overall population, represent-
ing a median reduction of 42.8% (Figure 5; absolute
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Figure 2. Changes in myocardial T2* (geometric mean ± 95% CI)
over two years in all patients (n=101) and in subgroups with base-
line T2* >5 to <10 ms (n=39), and T2* 10 to <20 ms (n=62). The
24-month value includes all patients who received study medication
and had an MR myocardial T2* measurement at baseline and post-
month 12, analyzed using LOCF analysis (n=95; 35 patients with
baseline T2* >5 to <10 ms and 60 patients with baseline T2* 10
to <20 ms).
Figure 3. Changes in LVEF (mean ± SD) over two years in all patients
(n=101) and in subgroups with baseline T2* >5 to <10 ms (n=39),
and T2* 10 to <20 ms (n=62). The 24-month value includes all
patients who received study medication and had an MR LVEF meas-
urement at baseline and post-month 12, analyzed using LOCF analy-
sis (n=95; 35 patients with baseline T2* >5 to <10 ms and 60
patients with baseline T2* 10 to <20 ms).
Figure 4. Changes in LIC (mean ± SD) over two years in all patients
(n=101) and in subgroups with baseline T2* >5 to <10 ms (n=39),
and T2* 10 to <20 ms (n=62). The 24-month value includes all
patients who received study medication and had an MR LIC meas-
urement at baseline and post-month 12, analyzed using LOCF analy-
sis (n=96; 35 patients with baseline T2* >5 to <10 ms and 61
patients with baseline T2* 10 to <20 ms).
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change from baseline –2,358 [range –12,795 to 25,127
ng/mL; P<0.001 LOCF). Decreases in serum ferritin were
observed in patient subgroups with baseline myocardial
T2* greater than 5 to less than 10 ms (7,185 at baseline and
3,614 ng/mL at two years, 42.8% reduction; absolute
change from baseline –2,707 [range –12,795 to 2,404
ng/mL]; P<0.001 LOCF) and T2* 10 to less than 20 ms
(4,893 at baseline to 2,565 ng/mL at two years, 44.8%
reduction; absolute change from baseline –1,868
[range –7,872 to 25,127 ng/mL]; P<0.001 LOCF). For
patients with serum ferritin data in the extension, 16
patients (15.8%) achieved serum ferritin levels of less than
1,000 ng/mL.
Safety
During the one-year core study, 9 patients discontinued
therapy as previously described.13 Of 101 patients who
entered the extension study, 86 (85.1%) completed two
years of treatment with deferasirox and 15 (14.9%) discon-
tinued. Of these patients, 9 (23.1%) had myocardial T2*
greater than 5 to less than 10 ms and 6 (9.7%) had a T2* 10
to less than 20 ms at baseline. Reasons for discontinuation
included unsatisfactory therapeutic effect (n=7), consent
withdrawal (n=4), abnormal laboratory result (n=1, no
improvement in myocardial T2* and raised alanine amino-
transferase), abnormal test procedure result (n=1, wors-
ened myocardial T2*), protocol violation (n=1) and lost to
follow up (n=1). Of the patients discontinuing due to
unsatisfactory therapeutic effect, the treating physician
noted a worsening of cardiac function or cardiac siderosis
in 2 patients. Furthermore, one patient listed as discontin-
uing due to consent withdrawal was noted to report no
improvement in liver or cardiac scan results prior to discon-
tinuation. No patients died during the 2-year study period.
The incidence of investigator-assessed drug-related AEs
occurring in over 5% of patients did not increase in the
one-year extension study relative to the one-year core
study even though the mean deferasirox dose in the exten-
sion study was higher than in the core study: increased
blood creatinine (extension: n=19 [18.8%] vs. core: n=22
[21.8%]), rash (extension: n=0 vs. core: n=15 [14.9%]) and
increased alanine aminotransferase (extension: n=4 [4.0%]
vs. core: n=6 [5.9%]). In patients receiving at least one
deferasirox dose increase to at least 40 mg/kg/d in either
the core or extension study, the most common drug-related
AEs and incidences were similar: increased blood creati-
nine (n=19 [21.1%]), increased alanine aminotransferase
(n=4 [4.4%]) and increased aspartate aminotransferase
(n=3 [3.3%]). There was no increase in the proportion of
drug-related AEs reported in patients achieving LIC less
than 7 mg Fe/g dw or serum ferritin levels of less than
1,000 ng/mL as compared with patients with higher iron
burdens (53.1% vs. 54.7% and 56.3% vs. 54.1%, respec-
tively). Two drug-related serious AEs were reported during
the one-year core study as previously reported (one nephri-
tis leading to acute renal failure and one renal tubular dis-
order, both resolved following drug discontinuation during
the core study).13 No drug-related serious AEs were report-
ed during the one-year extension. In total, 4 patients (4.0%)
had an increase in serum creatinine of greater than 33%
above baseline and the upper limit of normal (ULN) on two
consecutive visits (3 patients during the core and one dur-
ing the extension); there were no progressive increases in
these patients. The patient who had increased serum crea-
tinine greater than 33% above baseline and the ULN on
two consecutive visits during the extension, was receiving
deferasirox at 30 mg/kg/d and subsequently discontinued
by withdrawal of consent. Four patients (4.0%) had an
increase in alanine aminotransferase greater than 10 x ULN
on two consecutive visits (one patient during the core, 2
patients during the extension and one patient during both
the core and extension studies); alanine aminotransferase
levels were already elevated at baseline in all these
patients. For the 2 patients experiencing alanine amino-
transferase increases greater than 10 x ULN during the
extension, the percentage change in alanine aminotrans-
ferase levels from core baseline ranged from 159 to 260%
and 23 to 72%, respectively. Both patients were managed
with dose interruptions/decreases followed by dose titra-
tion back up to 40 mg/kg/d. The one patient with increases
in alanine aminotransferase greater than 10 x ULN in both
the core and extension discontinued the study due to an
unsatisfactory therapeutic effect; the percentage change in
alanine aminotransferase ranged from –42 to 49%. 
Discussion
This large study is the first to report prospective 2-year
data on cardiac iron removal for any iron-chelating agent.
Data show that continued treatment with deferasirox at
mean doses of over 30 mg/kg/d continued to significantly
increase myocardial T2* over the 2-year treatment period
compared with that achieved in the first year (17.7% in
the first year, 36.8% over two years). These improve-
ments in T2* resulted from a mean prescribed deferasirox
dose of 33.1±3.7 mg/kg/d during the 1-year core study
and 36.1±7.7 mg/kg/d during the 1-year extension. The
improvement in cardiac T2* by using higher doses of
deferasirox is comparable with high-dose data obtained
for deferiprone, as reported from a different trial.10 Of the
patients with moderate-to-mild myocardial iron overload
at baseline in the present study (cardiac T2* 10 to <20 ms),
57% achieved normal T2* of 20 ms or over at the end of
two years. Of interest, patients with severe myocardial
iron overload at baseline (T2* >5 to <10 ms) reached a
geometric mean of 8.7 ms, with 43% of patients achieving
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Figure 5. Changes in serum ferritin (median ± 25th/75th percentiles)
over two years in all patients (n=101) and in subgroups with base-
line T2* >5 to <10 ms (n=39), and T2* 10 to <20 ms (n=62). The
24-month value includes all patients who received study medica-
tion and had a serum ferritin measurement at baseline and post-
month 12, analyzed using LOCF analysis (n=101).
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moderate-to-mild myocardial T2* levels (10 to <20 ms) at
the end of two years, which is clinically important since a
myocardial T2* less than 10 ms compared with T2*
greater than 10 ms carries a significantly higher risk of
heart failure (relative risk of 160).8 For those with severe
cardiac iron overload at baseline who did not improve to
moderate-to-mild levels, or who required deferasirox
doses above the approved label dose (doses up to 40
mg/kg/d are currently approved by the US Food and Drug
Administration and the European Medicines Agency in
patients not adequately treated with doses of 30 mg/kg/d),
combination chelation therapy may offer an alternative
regimen for faster removal of cardiac iron compared with
monotherapies.11 Combination regimens of deferasirox
with deferoxamine are being investigated15 and a Phase II
multicenter study is being initiated. This notion supports
recent similar findings by Wood et al. who concluded that
more intensive combined iron chelation therapy may be
warranted in patients with severe cardiac and liver iron
overload.16 As all patients had previously received chela-
tion therapy, these results also suggest that deferasirox
may be a useful treatment for cardiac iron overload in
patients on other chelation therapies that have failed to
control cardiac iron accumulation.
The improvement in myocardial T2* was associated
with maintenance of normal cardiac function as deter-
mined by LVEF, as also shown in the 1-year core study.13 A
similar finding was also reported in an 18-month prospec-
tive study in severely iron-overloaded patients with β-tha-
lassemia.16 Maintenance of LVEF within the normal range
is different to the response seen with deferiprone or com-
bination therapy (deferiprone plus deferoxamine). The
exact reason for this difference remains to be elucidated,
although one explanation could be the greater access of
the small molecule deferiprone to mitochondria,17 where
iron overload may suppress activity of the respiratory
chain enzymes involved in the production of ATP.
Interestingly, however, an increase in right ventricular
ejection fraction measurements was seen with
deferasirox,18 but the relation of this change to the absence
of left ventricular functional improvement is not currently
understood. The data from the present study suggest that
improvement in LVEF with deferasirox may occur after
myocardial iron clearance is more complete, but further
studies are required to examine this issue. In addition, as
only patients with baseline LVEF within the reference
range for healthy adults were enrolled in the cardiac sub-
study, further studies would be required to evaluate
deferasirox therapy in patients with lower LVEF.
Significant reductions in cardiac iron levels were associ-
ated with concomitant continued decreases in serum fer-
ritin and hepatic iron burden over two years of deferasirox
therapy. In the 1-year core study, median serum ferritin
and mean LIC were reduced from baseline by 1,257
ng/mL and 6.6 mg Fe/g dw13 compared with a reduction
from core baseline of 2,358 ng/mL and 10.7 mg Fe/g dw,
respectively, in patients included in this 2-year extension
study. This represented a 42.8% and 38.8% reduction in
serum ferritin and LIC over two years of deferasirox treat-
ment, respectively. In patients with moderate-to-mild
baseline myocardial T2* (10 to <20 ms) completing two
years of treatment, median serum ferritin levels were
reduced from nearly 5,000 ng/mL to near the threshold of
2,500 ng/mL (2,565 ng/mL) that is associated with
increased morbidity and mortality.19,20 Furthermore, the
correlation between changes in LIC and myocardial T2*
suggests that patients with larger reductions in LIC show
better improvements in myocardial T2*, supporting prior
observations of a relationship between LIC and potential
cardiac risks.16,21
Deferasirox treatment was well tolerated, with the most
common drug-related AEs being increases in laboratory
parameters (blood creatinine and alanine aminotrans-
ferase) and rash. Notably, no deaths were reported over
this 2-year period of deferasirox therapy. Although
patients received mean deferasirox doses at the higher end
of the approved dose range (30–40 mg/kg/d), there was no
change in the AE profile, further supporting the positive
risk-benefit of high-dose deferasirox therapy for patients
with high cardiac and/or hepatic iron burden.16,22
The current study has some limitations. Inclusion crite-
ria for this trial enrolled only patients with LIC values
greater than 10 mg Fe/g dw and serum ferritin levels of
greater than 2,500 ng/mL. These criteria precluded the
assessment of efficacy of deferasirox in patients with
lower body iron burden. Other studies have, however,
shown favorable cardiac T2* responses in patients with
lower iron burden (LIC 10.7 mg Fe/g dw; serum ferritin
3,005 ng/mL).16 Due to dose escalation, by the end of the
second year, 66 (65.3%) patients were receiving
deferasirox doses of between 40 mg/kg/d and 51 mg/kg/d,
which are doses that are greater than the 40 mg/kg/d max-
imum currently approved by health authorities. Further
studies assessing the safety profile at higher doses are war-
ranted.
In conclusion, continued treatment with deferasirox
monotherapy for two years was effective in increasing
myocardial T2* by 36.8%, allowing 56.7% of patients
with moderate-to-mild baseline T2* to achieve normaliza-
tion of myocardial iron. Furthermore, 42.9% of patients
with severe myocardial iron overload were able to achieve
reduced myocardial iron levels corresponding to the mod-
erate-to-mild range, which is associated with a much
lower risk of cardiac complications. The ongoing exten-
sion of the EPIC cardiac substudy for an additional year
will further characterize the long-term cardiac efficacy and
safety of deferasirox for a total of three years.
Authorship and Disclosures
The information provided by the authors about contributions
from persons listed as authors and in acknowledgments is avail-
able with the full text of this paper at www.haematologica.org.
Financial and other disclosures provided by the authors using the
ICMJE (www.icmje.org) Uniform Format for Disclosure of
Competing Interests are also available at www.haematologica.org.
Appendix
Participating centers and investigators: Y. Aydinok, Ege
University Medical Faculty, Izmir, Turkey; L.L. Chan,
University Malaya Medical Centre, Lembah Pantai, Kuala
Lumpur, Malaysia; S. Chancharunee, Ramathibodi Hospital,
Mahidol University, Bangkok, Thailand; G. Chrousos, Athens
University Medical School, Athens, Greece; A. Kattamis, Athens
University Medical School, Athens, Greece; A. Chuansumrit,
Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;
M.S. Elalfy, Ain Shams University, Cairo, Egypt; A. El-
Beshlawy, Cairo University, Cairo, Egypt; R. Galanello,
Ospedale Regionale Microcitemie, Cagliari, Italy; H. Ibrahim,
Continued improvement in myocardial T2* with deferasirox
haematologica | 2011; 96(1) 53
Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; C.-K. Li,
Prince of Wales Hospital, Chinese University of Hong Kong,
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